av/aptevo-therapeutics--big.svg

NASDAQ:APVO

Aptevo Therapeutics

  • Stock

0.50

−5.85%

−1.56

USD last updated 13/08 01:59:42

Last Close

2.06

12/08 21:22

Market Cap

2.78M

Beta: 5.32

Volume Today

406.93K

Avg: 60.96K

PE Ratio

0.07

PFCF: −0.27

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company'...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -80-60-40-202018-12-312020-11-102021-12-312023-08-102024-11-07

    Revenue (Estimate*)

    5M10M2018-12-312020-11-102021-12-312023-08-102024-11-07

    *Estimate based on analyst consensus